BB-301

About Benitec Biopharma

Benitec Biopharma is a clinical-stage biotech focused on developing potentially curative, single-dose genetic medicines through its proprietary DNA-directed RNA interference (ddRNAi) platform. The company's lead candidate, BB-301, is in Phase 1b/2a development for Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic disorder with no approved therapies. Benitec's strategy leverages the convergence of gene therapy and RNAi to create long-lasting treatments, positioning it in a high-value niche within the advanced therapeutics landscape. Recent clinical updates show promising, durable efficacy signals, supporting the platform's potential.

Therapeutic Areas